Comparative risk of psoriatic arthritis in psoriasis patients on immunomodulators - PubMed
4 hours ago
- #psoriatic arthritis
- #psoriasis treatment
- #immunomodulators
- Psoriatic arthritis (PsA) is a rapidly progressive arthritis that is difficult to prevent and treat.
- The study assessed the 3-year risk of PsA in psoriasis patients on various immunomodulators including IL-12, 17, 23, tumor necrosis factor alpha, JAK1, and JAK3 inhibitors.
- IL-23 inhibitors (risankizumab, guselkumab, and ustekinumab) showed the greatest decreased risk of PsA development.
- Physicians can consider IL-23 inhibitors as treatment options for psoriasis patients with PsA risk factors to mitigate disease progression and improve quality of life.